Table 2. Network correlation scores P-values.

Cell line	Average patient	BV-173	Z-119	SUP-B15
BCR-ABL	-	p210	p190	p190
Profile	Max	BV-173	Z-119	Max
Dis.Model	Average	CCLE	Average	CCLE
Nilotinib	3.2E-1	2.7E-1	5.0E-1	4.4E-1
Dasatinib	2.9E-3	5.3E-4	4.9E-1	2.1E-2
Bosutinib	2.9E-2	1.3E-2	3.2E-1	7.7E-2
Bafetinib	1.8E-2	5.0E-3	6.1E-1	7.0E-2

Scores for correlation of drug-protein and disease-specific protein-protein interaction networks are dimension-less numbers. To bring all the scores of the 4 different drugs to a common scale we report their significance compared to a list of nonrelated diseases, the higher the impact of a drug on the disease network, the lower the reported P-value. Significant results (P-values ≤ 5%) are in bold and best significant result is underlined. BCR-ABL: Indicates BCR-ABL mutant. Profile: Target profile applied for correlation analysis as determined by chemical proteomics (Max stands for the maximum of the BV-173 and Z-119 profiles). Dis.Model: Disease-model applied for correlation analysis (Average stands for an average Ph+ ALL patient disease model with relative probabilities of disease gene deletions as reported by Mullighan et al.); CCLE stands for Cell line-specific Ph+ ALL disease-model taking into account the disease gene copy number as extracted from the Cancer Cell Line Encyclopedia (CCLE). The average patient model is used when no gene copy number information was deposited in CCLE.